The human T-cell leukemia virus type I (HTLV-I) is an onco-retrovirus that infects and transforms human CD4 T cells in vitro and in vivo. HTLV-I is the etiological agent of adult T-cell leukemia/lymphoma (ATLL), an aggressive and invariably fatal hematological disease. The virus is transmitted through sexual contact, contaminated blood and mother-to-child by breastfeeding, and is present in 20-30 million people worldwide. HTLV-I-mediated T-cell transformation arises from a multi-step oncogenic process in which the virus induces chronic T-cell proliferation, resulting in accumulation of genetic defects and deregulated cell growth. It is not yet fully understood how HTLV-I engenders ATLL, but the virus blocks the apoptotic network and expends the proliferative capacity of infected cells. HTLV-I infects and immortalizes primary human T cells in vitro and, after several months, these cells acquire the ability to grow in the absence of interleukin-2, referred to as transformation. We previously demonstrated that the viral oncogenic Tax can reactivate telomerase expression, an event required for long-term proliferation of HTLV-I-transformed cells in vitro and in vivo. This application will investigate the molecular events associated with deregulated telomerase activity and its role in the HTLV-I transformation process. Since telomerase reactivation represents one of the central steps in human carcinogenesis, results from this study will have broad application beyond viral oncogenesis.

Public Health Relevance

HTLV-I is associated with the development of an aggressive form of lymphocytic leukemia known as adult T- cell leukemia/lymphoma (ATLL). Although many features of HTLV-I biology have been discovered, the disease has no cure. Reactivation of telomerase activity is an essential step in the expansion and survival of HTLV-I- transformed cells in patients. Understanding the mechanisms involved in reactivation of telomerase activity by HTLV-I may uncover novel targets for the treatment of ATLL.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA201309-01A1
Application #
9174524
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2016-07-01
Project End
2021-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$336,555
Indirect Cost
$107,805
Name
University of Kansas
Department
Pathology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Yeh, Chien-Hung; Bellon, Marcia; Nicot, Christophe (2018) FBXW7: a critical tumor suppressor of human cancers. Mol Cancer 17:115
Bai, Xue Tao; Yeh, Chien-Hung; Nicot, Christophe (2017) NOTCH1 Activation Depletes the Pool of Side Population Stem Cells in ATL. J Cancer Sci 4:
Bellon, Marcia; Nicot, Christophe (2017) Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection. Viruses 9: